首页> 外文期刊>OncoTargets and therapy >Lentivirus-Mediated VEGF Knockdown Suppresses Gastric Cancer Cell Proliferation and Tumor Growth in vitro and in vivo
【24h】

Lentivirus-Mediated VEGF Knockdown Suppresses Gastric Cancer Cell Proliferation and Tumor Growth in vitro and in vivo

机译:慢病毒介导的VEGF敲低抑制胃癌细胞增殖和体外肿瘤生长抑制胃癌细胞增殖和肿瘤生长

获取原文
       

摘要

Purpose: Gastric cancer has a high mortality rate worldwide. Although treatments, such as molecular-targeted therapy, have been introduced, the resulting long-term survival and prognosis remain unsatisfactory. Downregulation of the target genes using lentivirus-mediated short hairpin RNA (shRNA) can be an effective therapeutic strategy for patients with gastric cancer. Overexpressed vascular endothelial growth factor A (VEGF) in human gastric cancer cells can be an effective novel therapeutic target for human gastric cancer. Thus, this study aimed to evaluate the therapeutic effects of lentivirus-mediated knockdown of VEGF gene expression in human gastric cancer growth. Materials and Methods: Specific shRNA sequences targeting VEGF were designed to construct a lentiviral expression vector. After human gastric carcinoma cells (cell line NCI-N87) were infected with the lentiviral vector, the therapeutic effects of the lentivirus-mediated shRNA targeting VEGF were analyzed both in vitro and in vivo. Results: Stable suppression of VEGF gene expression in NCI-N87 cells using shRNA (ShVEGF) showed significant inhibition of cell proliferation, clonogenicity, and cell motility. ShVEGF also showed increased G0/G1 cell cycle arrest and apoptosis. In addition, in vivo results from nude mice xenografted ShVEGF showed significant inhibition of tumor growth. Assessing the therapeutic effects of intratumoral injection of lentivirus-targeting VEGF (Virus_VEGF) revealed that it significantly inhibited tumor growth compared to that in the Virus_Scramble or saline injection control groups. Conclusion: The constructed ShVEGF showed significant inhibition of NCI-N87 gastric cancer cell growth both in vitro and in vivo. These experimental results suggest a novel therapeutic strategy for patients with gastric cancer using lentivirus-mediated shRNA targeting VEGF.
机译:目的:全世界胃癌具有高死亡率。虽然已经引入了诸如分子靶向治疗的治疗,但由此产生的长期存活和预后仍然不令人满意。使用Lentivirus介导的短发夹RNA(ShRNA)的靶基因下调可以是胃癌患者的有效治疗策略。人胃癌细胞中过表达血管内皮生长因子A(VEGF)可以是人胃癌的有效的新疗法靶标。因此,本研究旨在评估慢病毒介导的VEGF基因表达在人胃癌生长中的抑制的治疗效果。材料和方法:靶向VEGF的特异性shRNA序列被设计成构建慢病毒表达载体。在用慢病毒载体感染人胃癌细胞(细胞系NCI-N87)之后,在体外和体内分析诱导慢病毒介导的ShRNA靶向VEGF的治疗效果。结果:使用ShRNA(Shvegf)的NCI-N87细胞VEGF基因表达的稳定抑制显示出对细胞增殖,克隆根和细胞运动性的显着抑制。 Shvegf还表现出G0 / G1细胞周期停滞和凋亡增加。此外,在裸鼠的体内裸鼠卵黄移植的Shvegf表现出肿瘤生长的显着抑制。评估脑内注射Lentivirus靶向VEGF(VIRUS_VEGF)的治疗效果表明,与病毒或盐水注射对照组中的肿瘤生长显着抑制了肿瘤生长。结论:构建的Shvegf在体外和体内均显示出NCI-N87胃癌细胞生长的显着抑制。这些实验结果表明,使用慢病毒介导的ShRNA靶向VEGF的胃癌患者的新疗效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号